Texas at­tor­ney gen­er­al an­nounces $42.7M set­tle­ment with Take­da, Bax­ter over AD­HD drug 

Bax­ter In­ter­na­tion­al and Take­da agreed to pay $42.7 mil­lion Tues­day to set­tle with the Texas at­tor­ney gen­er­al over al­le­ga­tions that the com­pa­nies paid clin­i­cians to rec­om­mend Take­da’s AD­HD drug Vy­vanse.

The Civ­il Med­ic­aid Fraud Di­vi­sion with­in the Texas at­tor­ney gen­er­al’s of­fice — which al­so names Take­da sub­sidiaries Shire, Vi­rophar­ma and Bax­al­ta — said in a re­lease that the set­tle­ment re­solves al­le­ga­tions that the com­pa­nies vi­o­lat­ed the state’s Med­ic­aid Fraud Pre­ven­tion Act, or the TMF­PA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER